Researchers develop a "surveillance system" to monitor patients' electronic health records for signs of undiagnosed hypertension.
MASSDEVICE ON CALL — A computer algorithm may be able to help physicians monitor patients for signs of hypertension, a disease known as "the silent killer."
Researchers at Northwestern Medicine developed a trio of algorithms to review patients' electronic health records and alert healthcare providers that a patient may have or may be developing hypertension.
Twitter-savvy physicians and researchers mull over the latest clinical results for Medtronic's renal denervation technology, calling for more common sense and less hype in treating hypertension.
Doctors and researchers at this year's EuroPCR conference look for answers in Medtronic's landmark SYMPLICITY HTN-3 clinical trial, which failed to find that renal denervation works against hypertension.
Amid the hand-wringing and back-pedaling surrounding renal denervation, some physicians are still looking for ways to use the technology to treat patients with hypertension.
St. Jude Medical says that its next-gen EnligHTN renal denervation system appears safe and effective in treating hypertension, but docs at this year's EuroPCR conference are calling for more robust clinical trials.
The marketing push for hypertension-treating renal denervation technology, clinical darling turned black sheep, has some doctors raising eyebrows at the EuroPCR conference in Paris this week.
Attendees at this year's EuroPCR conference in Paris cast a wary eye on medical device makers' efforts to promote renal denervation in treatment of hypertension, taking to Twitter to note and sometimes chide companies for putting "marketing before science."
Boston Scientific, Medtronic and Covidien take millions in write-downs on their renal denervation assets after the failure of Medtronic's Symplicity-3 trial.
Dr. George Bakris, co-principal investigator in Medtronic's Symplicity-3 trial, says renal denervation needs more study before attempting more clinical trials.
MASSDEVICE ON CALL — Dr. George Bakris, the co-principal investigator for Medtronic's (NYSE:MDT) failed Symplicty-3 renal denervation trial, believes further clinical work should be tabled until a few key questions about the therapy are answered.